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ABSTRACT Hemophilia BCha 1 Hill is a mild hereditary hem-
orrhagic disorder in which the factor IX antigen is present in
normal amounts but factor LX biological activity is markedly re-
duced. Previous studies have demonstrated that purified factor
IXCha.eI Hill has 8% of the activity of normal human factor LX and
that the activation of factor IXChapel Hill is defective in that only
one of the two peptide bonds hydrolyzed during activation of nor-
mal factor IX is cleaved. The tryptic peptides from normal human
factor IX and factor IXChpel Hill were subjected to analysis by high-
performance liquid chromatography. Comparison of the elution
profile of the peptides obtained from factor LXChapel Hill and nor-
mal factor IX demonstrated that the tripeptide Leu-Thr-Arg, which
is derived from the normal molecule (positions 143-145) imme-
diately amino-terminal from the Arg-Ala peptide bond at 145-146
that is cleaved during the activation of factor LX with factor Ma,
was absent in the digest obtained from factor IXChapel Hill. The
elongated "activation peptide" from factor LXChapel Hill was ob-
tained by further high-performance liquid chromatographic frac-
tionation and subjected to primary structure analysis. The follow-
ing sequence, corresponding to positions 143-147, was obtained:
Leu-Thr-His-Ala-Glu. Thus, the primary molecular defect in fac-
tor IXChapel Hill is the substitution of histidine for arginine at po-
sition 145. This substitution precludes cleavage by factor Ma at
this peptide bond, and the activation peptide region remains as-
sociated with the light chain of factor IXachapel Hilly
Blood coagulation factor IX is a glycoprotein of M, 57,000 that
participates during the middle phase of intrinsic blood coag-
ulation (1-3). Factor IX circulates as an inactive precursor or
zymogen form; upon activation with either factor XIa and cal-
cium ions or tissue factor/factor VIIa and calcium ions, two
peptide bonds (Arg-Ala at position 145-146 and Arg-Val at po-
sition 180-181) are cleaved with the release of an activation
peptide and the formation of factor IXa (4-7). Factor IXa is a
serine protease composed of two polypeptide chains, a "light
chain" consisting of the amino-terminal 145 residues of factor
IX and containing the 12 y-carboxyglutamic acid residues con-
nected by a disulfide bridge to a "heavy chain" consisting of the
carboxyl-terminal 236 residues of factor IX. The "heavy chain"
contains the residues actually involved in the process of catal-
ysis and demonstrates a high degree of homology with the heavy
chains of the other vitamin K-dependent coagulation factors and
the chymotrypsin family of proteases (8, 9). Factor IXa in turn
activates factor X in a reaction requiring the presence of cal-
cium ions, phospholipid, and factor VIII (2, 3).
Individuals with Christmas disease (hemophilia B; deficiency
of factor IX activity) can be divided into several classes: cross-
reacting material-positive (CRM+) individuals who possess nor-
mal levels of factor IX protein as assessed by immunological
assay but decreased-to-undetectable levels of factor IX coag-
ulant activity; CRM- individuals with greatly reduced or un-
detectable levels of both factor IX activity and factor IX antigen;
and CRM' individuals with variably reduced levels of both fac-
tor IX activity and factor IX antigen (1, 10, 11).
Our laboratory has been interested in the study of CRM'
variants with the goal of elucidating the nature of the molecular
defect(s) and using this information to establish relationships
between chemical structure and biological function in factor IX.
Recent work has focused on one of these CRM+ variants, factor
IXChapel Hill. This abnormal protein has been purified by tech-
niques developed for the purification of normal human factor
IX and has been characterized partially (12). More recent stud-
ies (13) have shown that factor IXChapel Hill is activated by factor
XIa in the presence of calcium ions but, in contrast to normal
factor IX, only the Arg-Val bond at position 180-181 is cleaved.
The present study demonstrates that there is the substitution
of a histidine for the arginine at position 145, thus explaining
the lack of cleavage at this position in factor IXChapel Hill
MATERIALS AND METHODS
Normal human factor IX and factor IXChapel Hill were purified
to homogeneity by published procedures (12, 14). Trypsin (L-1-
tosylamide-2-phenylmethyl chloromethyl ketone-treated tryp-
sin, 222 units/mg; 92% protein) was obtained from Worthing-
ton and was allowed to stand at ambient temperature (240C) in
0.001 M HCI for 2 hr prior to use (15). Urea was recrystallized
from water after treatment with a mixed-bed ion-exchange resin
(Bio-Rad AG501-X8) prior to use (16).
Proteins were taken into 10% acetic acid (vol/vol) by di-
alysis, Iyophilized, and then reduced and carboxymethylated as
described by Canfield and Anfinsen (17). Tryptic hydrolysis was
performed with a 1:20 (wt/wt) ratio of enzyme to substrate pro-
tein in 0.1 MI NH4HCO3 for 16 hr at 370C. The hydrolysis re-
action was terminated by the addition of glacial acetic acid to
pH 4.0, and the reaction mixture was then Iyophilized. Because
small amounts of proteins were used (2-4 nmol), all of the above
manipulations were performed in the same reaction vessel (18).
The tryptic hydrolysates were analyzed by high-performance
liquid chromatography with a Beckman-Altex 324 liquid chro-
matographic system. The initial analysis (19) was performed by
using a 4.6 X 250 mm Ultrasphere-ODS column (Beckman) at
250C with a flow rate of 1.0 ml/min. The initial solvent was
0.05 M sodium phosphate (pH 2.87). Elution was accomplished
with a linear gradient to 28% acetonitrile in 114 min and then
to 62% acetonitrile in 30 min. Rechromatography of isolated
peptides prior to primary structure analysis utilized a 4.6 x 250
mm Vydac TP C8 5-gm column (The Separations Group, Hes-
peria, CA). The initial solvent was 0.1% trifluoroacetic acid.
Abbreviation: CRM, crossreacting material.
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Elution in a linear gradient to 60% 2-propanol was accom-
plished in 120 min at 450C with a flow rate of 1.0 ml/min. Ab-
sorbance was monitored at 210 and 280 nm.
The isolated peptides were subjected to automated Edman
degradation (20) in a Beckman 890C protein/peptide sequen-
cer. The 0.1 M Quadrol program of Brauer et al. (21) was used
with modification of the cleavage cycle to minimize blowing of
heptafluorobutyric acid vapor through the effluent valve.
Polybrene (Aldrich) was used as a carrier (22, 23); 3 mg was dried
from aqueous solution in the sequencer cup and run through
one complete cycle before the sample- was loaded. We iden-
tified the phenylthiohydantoin derivatives of amino acids pro-
duced by the Edman degradation by HPLC using the 4.6 x 250
mm Ultrasphere-ODS column with detection at 254 and 323
nm and using gradient elution at 55C with an acetate/acetoni-
trile solvent system (24).
RESULTS
The HPLC analysis of the peptides derived from the tryptic
hydrolysis of reduced and carboxymethylated normal human
factor IX is shown in Fig. 1B. This pattern is reproducible and
has been obtained for several different preparations of factor
IX. The HPLC analysis of the peptides derived from the tryptic
hydrolysis of reduced and carboxymethylated factor IXChapel Hill
is shown in Fig. 1A. As can be observed, there is a single pep-
tide missing from the early portion of the chromatogram as in-
dicated by the arrow. We previously had determined that this
A
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FIG. 1. Tryptic peptides of factor IXChapel Hill and normal human
factor IX. The separation of the tryptic peptides from reduced and car-
boxymethylated factor IXChapel Hill (A) and normal factor IX (B) was ac-
complished by reverse-phase chromatography on Ultrasphere-ODS in
a phosphate buffer/acetonitrile solvent gradient as described. The ver-
tical arrow indicates the elution position of the peptide Leu-Thr-Arg
obtained from the tryptic hydrolysis of normal factor IX. The eluent
from the region within the bars in A was collected and subjected to a
second chromatographic fractionation as shown in Fig. 2.
Table 1. Primary structure, surrounding peptide bonds in factor
IX cleaved by factor XIa*
140 145
rg-Ala Human Thr-Ser -Lys-Leu-Thr-Arg-Ala-Glu-Ala
146
Bovine Ser -Lys-Lys-Leu-Thr-Arg-Ala-Glu-Thr
175 180
Arg-Val Human Phe-Asn-Asp-Phe-Thr-Arg-Val-Val-Gly-Gly
181
Bovine Phe-Asp-Glu-Phe-Ser-Arg-Val-Val-Gly-Gly
Data for the bovine protein is from ref. 8. The data for the human pro-
tein was obtained from analysis of cDNA (25).
was a tripeptide, Leu-Thr-Arg, derived from the portion of the
factor IX molecule immediately amino-terminal from the Arg-
Ala peptide bond at 145-146, which is cleaved by factor XIa
during the formation of factor IXa as shown in Table 1. The ma-
jority of the other peptides had been identified previously by
primary structure analysis (unpublished data) and are in agree-
ment with the primary structure determined from nucleotide
sequence analysis of eDNA for human factor IX (26). The ma-
terial within the bars of Fig. 1A was subjected to a second HPLC
analysis as shown in Fig. 2. The material within the bars was
collected and subjected to primary structure analysis as shown
in Table 2. The amino acid sequence derived from the analysis
of this peptide is compared to that of normal human factor IX.
From this analysis it is clear that the defect in factor IXChapel Hill
is a result of the substitution of a histidyl residue for an arginyl
residue at position 145. This substitution precludes cleavage bv
either trypsin or factor XIa under the present reaction condi-
tions.
The activation peptide of normal human factor IX contains
no internal lysine or arginine and is, therefore, a single 35-res-
idue tryptic peptide. Thus, the variant peptide in the tryptic
digest of factor IXChapel Hill is a 38-residue peptide consisting of
the last three residues of the light chain plus the activation pep-
tide.
10 20 30 40 50 60 70
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FIG. 2. Rechromatography of the eluent containing the variant
peptide. The portion ofthe eluent indicated in Fig. 1A was concentrated
to about 1 ml and rerun on a Vydac TP C8 column in a 0.1% trifluo-
roacetic acid/2-propanol solvent gradient as described. The material
indicated was subjected to primary structure analysis.
Biochemistrv: Noves et al.
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Table 2. Amino-terminal sequence of variant peptide from
factor IXChap.1 Hill
Variant peptide Normal
Amount, human
Cycle Found nmol factor IX*
1 Leu 0.26
2 Thr NQt
3 His 0.11
4 Ala 0.22
5 Glu 0.12
6 Ala 0.19
7 Val 0.22
8 Phe 0.18
9 Pro 0.05
10 Asp 0.14
11 Val 0.16
12 Asp 0.14
13 Tyr 0.13
14 Val 0.11
Leu
Thr
Arg
Ala
Glu
Ala
Val
Phe
Pro
Asp
Val
Asp
Tyr
Val
About 50% of the peak indicated in Fig. 3 was subjected to Edman
degradation.
* From ref. 25.
t NQ, not quantitated.
DISCUSSION
The above results suggest that the physiological defect in hem-
ophilia BChapel Hill is due to the failure of the Arg-Ala peptide
bond at position 145-146 to be cleaved during the process of
coagulation because of the substitution of histidine for arginine
at position 145. The substitution of a histidine for an arginine
residue can be the result of a point mutation resulting from a
single nucleotide change in the codon responsible for position
145 in the factor IX polypeptide chain. In the case of factor
IXChapel Hill, the change is likely from C-G-T to C-A-T. As pre-
viously demonstrated by work in this laboratory (13), the ac-
tivation of factor IXChapel Hill results in a two-chain molecule with
a structure similar to that reported for bovine factor IXaa, the
activation product formed from the activation of factor IX with
the coagulant protein from Russell's Viper Venom (6). Lind-
quist et al. reported that bovine factor IXaa has equally reduced
esterase activity N'-tosyl-L-arginine methyl ester and coagulant
activity as compared to bovine factor IXaMP (6). Byrne et al. (26)
subsequently reported that, in the presence of calcium ions,
there is essentially no difference in the hydrolysis of Na-ben-
zoyl-L-arginine ethyl ester by bovine factor IXaa and factor IXaM3.
Further work from Castellino's laboratory (F. J. Castellino,
personal communication) has shown that both bovine factor IXaa
and factor IXaM effectively hydrolyze the thioester substrates
developed by Powers and co-workers (27). With the bovine
proteins there is a clear difference in their effectiveness in the
activation of factor X in the presence of cofactors, with factor
IXaa being much less effective than factor IXaM (F. J. Castel-
lino, personal communication). In studies with the human pro-
tein, DiScipio et al. (7) presented evidence that there is no dif-
ference in the activity of factor IXaa and factor IXap in the
catalysis of reactions in the intrinsic coagulation pathway. It would
seem reasonable that factor IXachapel Hill should have enzymatic
properties similar to human factor IXaa. It is clear that a more
rigorous comparison of the catalytic properties of human factor
IXaa and factor IXaMP is required before a meaningful relation-
ship can be established between normal human factor IXaa and
factor IXachapel Hill
Although we have not observed cleavage-of the His-Ala bond
at position 145-146 either in our present studies with trypsin
or in previous studies.on the interaction of factor XIa with factor
LXChapel Hill (13), it is possible that cleavage of the bond could
be accomplished with higher amounts of factor XIa or with fac-
tor VIIa/tissue factor. In this regard, it is of interest to note that
Shafer's laboratory (28) has reported the substitution of histi-
dine for arginine at residue 16 in the A (a) chain of fibrinogen
Petoskey, forming a peptide bond that is slowly cleaved by
thrombin.
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